Redmond Asset Management’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Redmond Asset Management’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,392	Closed	-$12K	–	178
2022 Q3	$12K	Sell	1,392 -88	-6%	-$1.02K	﹤0.01%	171
2022 Q2	$19K	Sell	1,480 -229	-13%	-$3.61K	0.01%	186
2022 Q1	$44K	Buy	1,709 +109	+7%	+$3.22K	0.01%	189
2021 Q4	$73K	Buy	1,600 +54	+3%	+$3.68K	0.02%	196
2021 Q3	$142K	Buy	1,546 +35	+2%	+$3.62K	0.04%	184
2021 Q2	$218K	Sell	1,511 -3	-0.2%	-$752	0.06%	184
2021 Q1	$425K	Buy	+1,514	New	+$444K	0.13%	164

Other funds holding KRBP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redmond Asset Management's KRBP Position: Q4 2022 in Review

Redmond Asset Management sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q4 2022, closing a stake of 1,392 shares — an estimated $12K sold.

Redmond Asset Management first reported a position in KRBP in Q1 2021 and held it in 7 quarters. The position peaked at $425K in Q1 2021. 12 funds tracked by Wall St. Rank hold KRBP as of Q4 2022.

Redmond Asset Management reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Redmond Asset Management sold 1,392 Kiromic BioPharma, Inc. Common Stock shares in Q4 2022, an estimated $12K.
Redmond Asset Management first reported a position in Kiromic BioPharma, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Redmond Asset Management's Kiromic BioPharma, Inc. Common Stock position peaked at $425K in Q1 2021.
12 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q4 2022.

Based on Redmond Asset Management's 13F filing for Q4 2022, filed 6 Feb 2023.